Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Ejemplares similares

• Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
  por: Atsumi, Tatsuya, et al.
  Publicado: (2017)
• Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study
  por: Sarzi-Puttini, Piercarlo, et al.
  Publicado: (2018)
• The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
  por: Fleischmann, Roy
  Publicado: (2009)
• Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
  por: Tanaka, Yoshiya, et al.
  Publicado: (2020)
• The preclinical evaluation of immunocontraceptive vaccines based on canine zona pellucida 3 (cZP3) in a mouse model
  por: Wang, Ying, et al.
  Publicado: (2018)